Single-Port Versus Multi-Port Robotic Retroperitoneal Partial Nephrectomy: A Propensity Score-Matched Comparison
<b><i>Objective:</i></b> To compare the surgical results of retroperitoneal (RP) robot partial nephrectomy (PNx) using either a single-port robot (SP) or a multi-port robot (MP). <b><i>Materials and Methods:</i></b> We retrospectively reviewed all RP robotic PNx performed at a single institution from September 2021-when the SP robot was introduced to the institution-through April 2023. In total, 125 patients underwent the surgery; 81 patients were treated with surgery using a MP robot whereas 44 patients were treated with surgery using a SP. All MP surgeries were performed with da Vinci Xi (Intuitive, Sunnyvale, California, USA), while all SP surgeries were performed with da Vinci SP (Intuitive, Sunnyvale, California, USA). We performed a propensity score-matching (PSM) analysis of these 125 patients. <b><i>Results:</i></b> There was no significant difference between the two groups after PSM. In terms of operation time, that for MP was 103.68 ± 21.89 minutes whereas that for SP was 95.43 ± 32.22 minutes (<i>p</i>-value = 0.164). Meanwhile, in terms of console time, that for MP was 70.95 ± 21.92 minutes whereas that for SP was 64.14 ± 32.06 minutes (<i>p</i>-value = 0.248). In terms of estimated blood loss was 90.91 ± 91.06 mL in MP and 92.27 ± 104.30 mL in SP (<i>p</i>-value = 0.948). Lastly, there was a statistically significant difference in warm ischemic time, as it was 17.18 ± 6.56 minutes in MP and 13.82 ± 4.59 in SP (<i>p</i>-value = 0.007). There were no statistically significant differences between MP and SP in any other surgical outcomes. <b><i>Conclusions:</i></b> SP robot RP PNx demonstrated comparable outcomes to those achieve using MP procedures. This means SP robot RP PNx can be considered a preferable and more convenient surgical approach than conventional methods, particularly when dealing with small renal masses located in the posterior side of the kidney.
Authors
- Sung‐Hoo Hong (ORCID: https://orcid.org/0000-0002-1952-4010)
- Jiwoong Yu (ORCID: https://orcid.org/0000-0003-2147-2915)
- Seokhwan Bang (ORCID: https://orcid.org/0000-0002-0450-8763)
- U‐Syn Ha (ORCID: https://orcid.org/0000-0001-9930-0588)
- Dong‐Ho Shin (ORCID: https://orcid.org/0000-0001-8496-8825)
- Hyuk Jin Cho (ORCID: https://orcid.org/0000-0003-2599-2950)
- Ji Youl Lee (ORCID: https://orcid.org/0000-0001-6775-1157)
- Hoyoung Bae (ORCID: https://orcid.org/0000-0001-7837-4000)
- Yong-Hyun Park (ORCID: https://orcid.org/0000-0003-4611-716X)
Institutions
- Seoul National University (KR)
- Seoul Metropolitan Government (KR)
- Samsung Medical Center (KR)
- SNUH SMG-SNU Boramae Medical Center (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Sungkyunkwan University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Journal of Endourology
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1089/end.2024.0493
- Citations
- 12
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.03